Compare Regeneron Pharmaceuticals Inc (REGN) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Snap On Incorporated — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while Snap On Incorporated trades at $360.27 (market cap $18.62B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.1× Snap On Incorporated's market cap, and Snap On Incorporated pays the higher dividend (2.71%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Snap On Incorporated for 36 Days on average.
| REGN | SNA | |
|---|---|---|
Market Cap | $76.40B | $18.62B |
Volume | 626,381 | 360,121 |
Sector | Health | Industrials |
52-Week High | $852.03 | $419.31 |
52-Week Low | $557.73 | $327.33 |
Typical Hold Time | 107 Days | 36 Days |
Enterprise Value | $71.12B | $18.25B |
Dividend Yield | 0.51% | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Snap-on Incorporated (SNA) trades at $359.89, down 2.37% on the day, with a bearish technical signal from moving averages and oscillators. Fundamentally, the company maintains strong profitability with a 19.6% net income margin and a 17.58% ROE, though Q1 2026 earnings slightly missed expectations. Recent news highlights gross margin expansion and institutional position adjustments.
The outlook is supported by analyst consensus with a $449 price target and 66.7% buy ratings, but risks include valuation premiums and mixed segment trends. Earnings growth from innovation and RCI initiatives remains a key catalyst, though integration costs and softer OEM demand pose execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
